Details of the Drug

General Information of Drug (ID: DML72VJ)

Drug Name
GW685698X
Synonyms
Allermist; Avamys; Veramyst; Fluticasone furoate; GW 685698X; GW6; GW-685698; GW-685698X; Veramyst (TN); Fluticasone furoate (JAN/USAN/INN); (6alpha,11beta,16alpha,17alpha)-6,9-Difluoro-17-(((fluoromethyl)thio)carbonyl)-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl-2-furancarboxylate; 6alpha,9-Difluoro-17-(((fluoromethyl)sulfanyl)carbonyl)-11beta-hydroxy-16alpha-methyl-3-oxoandrosta-1,4-dien-17alpha-yl furan-2-carboxylate
Indication
Disease Entry ICD 11 Status REF
Allergic rhinitis CA08.0 Approved [1]
Asthma CA23 Approved [2]
Affected Organisms
Humans and other mammals
ATC Code
R01AD12: GW685698X
R01AD: Corticosteroids
R01A: DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01: NASAL PREPARATIONS
R: RESPIRATORY SYSTEM
R03BA09: GW685698X
R03BA: Glucocorticoids
R03B: OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS
R03: DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R: RESPIRATORY SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 538.6
Logarithm of the Partition Coefficient (xlogp) 4.8
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 10
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 3 h [3]
Bioavailability
The bioavailability of drug is 50% [3]
Clearance
The clearance of drug is 57.8 L/h [4]
Elimination
More than 90% of drug is eliminated in the feces and 1-2% in the urine []
Half-life
The concentration or amount of drug in body reduced by one-half in 15.1 hours []
Metabolism
The drug is metabolized via the hepatic [5]
Vd
The volume of distribution (Vd) of drug is 608 L []
Chemical Identifiers
Formula
C27H29F3O6S
IUPAC Name
[(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate
Canonical SMILES
C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)SCF)OC(=O)C5=CC=CO5)C)O)F)C)F
InChI
InChI=1S/C27H29F3O6S/c1-14-9-16-17-11-19(29)18-10-15(31)6-7-24(18,2)26(17,30)21(32)12-25(16,3)27(14,23(34)37-13-28)36-22(33)20-5-4-8-35-20/h4-8,10,14,16-17,19,21,32H,9,11-13H2,1-3H3/t14-,16+,17+,19+,21+,24+,25+,26+,27+/m1/s1
InChIKey
XTULMSXFIHGYFS-VLSRWLAYSA-N
Cross-matching ID
PubChem CID
9854489
ChEBI ID
CHEMBL1676
CAS Number
397864-44-7
UNII
JS86977WNV
DrugBank ID
DB08906
TTD ID
D0Y7JU
VARIDT ID
DR00324
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glucocorticoid receptor (NR3C1) TTYRL6O GCR_HUMAN Agonist [6]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Allergic rhinitis
ICD Disease Classification CA08.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Glucocorticoid receptor (NR3C1) DTT NR3C1 7.57E-01 -0.04 -0.07
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
2 ClinicalTrials.gov (NCT00539006) Comparator Study Evaluating Patient Preference Of FFNS vs. FPNS. U.S. National Institutes of Health.
3 Health Canada Product Monograph: Zaditen (ketotifen fumarate) for oral administration
4 Allen A, Bareille PJ, Rousell VM: Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate. Clin Pharmacokinet. 2013 Jan;52(1):37-42. doi: 10.1007/s40262-012-0021-x.
5 Sullivan HR, Billings RE, McMahon RE: Metabolism of cephalexin-14C in mice and in rats. J Antibiot (Tokyo). 1969 May;22(5):195-200.
6 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).